{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:07:27Z","timestamp":1791338847983,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T00:00:00Z","timestamp":1469577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/leu.2016.202","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T03:25:11Z","timestamp":1469589911000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-4750","authenticated-orcid":false,"given":"S","family":"Eldfors","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kuusanm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kontro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Edgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Pemovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-0332","authenticated-orcid":false,"given":"O","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4843-2876","authenticated-orcid":false,"given":"T","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"key":"BFleu2016202_CR1","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2015-01-567842","volume":"125","author":"M M\u00fcschen","year":"2015","unstructured":"M\u00fcschen M . Rationale for targeting the pre\u2013B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood 2015; 125: 3688\u20133693.","journal-title":"Blood"},{"key":"BFleu2016202_CR2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V87.4.1211.bloodjournal8741211","volume":"87","author":"SP Hunger","year":"1996","unstructured":"Hunger SP . Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996; 87: 1211\u20131224.","journal-title":"Blood"},{"key":"BFleu2016202_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0092-8674(84)90078-3","volume":"36","author":"DL Williams","year":"1984","unstructured":"Williams DL, Look AT, Melvin SL, Roberson PK, Dahl G . New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia. Cell 1984; 36: 101\u2013109.","journal-title":"Cell"},{"key":"BFleu2016202_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ccell.2015.02.003","volume":"27","author":"H Geng","year":"2015","unstructured":"Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S et al. Self-enforcing feedback activation between BCL6 and Pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 2015; 27: 409\u2013425.","journal-title":"Cancer Cell"},{"key":"BFleu2016202_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","volume":"22","author":"VT Bicocca","year":"2012","unstructured":"Bicocca VT, Chang BH, Masouleh BK, M\u00fcschen M, Loriaux MM, Druker BJ et al. Crosstalk between ROR1 and the pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012; 22: 656\u2013667.","journal-title":"Cancer Cell"},{"key":"BFleu2016202_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3324\/haematol.2009.011346","volume":"95","author":"T Burmeister","year":"2010","unstructured":"Burmeister T, G\u00f6kbuget N, Schwartz S, Fischer L, Hubert D, Sindram A et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010; 95: 241\u2013246.","journal-title":"Haematologica"},{"key":"BFleu2016202_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013; 3: 1416\u20131429.","journal-title":"Cancer Discov"},{"key":"BFleu2016202_CR8","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep 2014; 4: 5193.","journal-title":"Sci Rep"},{"key":"BFleu2016202_CR9","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HLM Koskela","year":"2012","unstructured":"Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanm\u00e4ki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905\u20131913.","journal-title":"N Engl J Med"},{"key":"BFleu2016202_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568\u2013576.","journal-title":"Genome Res"},{"key":"BFleu2016202_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2014","unstructured":"Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. Fly 2014; 6: 80\u201392.","journal-title":"Fly"},{"key":"BFleu2016202_CR12","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/gb-2011-12-1-r6","volume":"12","author":"H Edgren","year":"2011","unstructured":"Edgren H, Murum\u00e4gi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 2011; 12: R6.","journal-title":"Genome Biol"},{"key":"BFleu2016202_CR13","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43: D805\u2013D811.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2016202_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1042\/BJ20112214","volume":"443","author":"MA Whitehead","year":"2012","unstructured":"Whitehead MA, Bombardieri M, Pitzalis C, Vanhaesebroeck B . Isoform-selective induction of human p110\u03b4 PI3K expression by TNF\u03b1: identification of a new and inducible PIK3CD promoter. Biochem J 2012; 443: 857\u2013867.","journal-title":"Biochem J"},{"key":"BFleu2016202_CR15","doi-asserted-by":"publisher","first-page":"e5145","DOI":"10.1371\/journal.pone.0005145","volume":"4","author":"K Kok","year":"2009","unstructured":"Kok K, Nock GE, Verrall EAG, Mitchell MP, Hommes DW, Peppelenbosch MP et al. Regulation of p110\u03b4 PI 3-kinase gene expression. PLoS One 2009; 4: e5145.","journal-title":"PLoS One"},{"key":"BFleu2016202_CR16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ng.3362","volume":"47","author":"U Fischer","year":"2015","unstructured":"Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz H-J et al. Genomics and drug profiling of fatal TCF3-HLF\u2212positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet 2015; 47: 1020\u20131029.","journal-title":"Nat Genet"},{"key":"BFleu2016202_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads MB, Gatenby RA, Dalton WS . Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9: 665\u2013674.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016202_CR18","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1038\/sj.onc.1210120","volume":"26","author":"SA Mehta","year":"2006","unstructured":"Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ, Broxmeyer HE, Kopelovich L et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene 2006; 26: 3329\u20133337.","journal-title":"Oncogene"},{"key":"BFleu2016202_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.12883","volume":"166","author":"LCJ van den Berk","year":"2014","unstructured":"van den Berk LCJ, van der Veer A, Willemse ME, Theeuwes MJGA, Luijendijk MW, Tong WH et al. Disturbed CXCR4\/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. Br J Haematol 2014; 166: 240\u2013249.","journal-title":"Br J Haematol"},{"key":"BFleu2016202_CR20","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","volume":"11","author":"EAR Sison","year":"2013","unstructured":"Sison EAR, McIntyre E, Magoon D, Brown P . Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res 2013; 11: 1004\u20131016.","journal-title":"Mol Cancer Res"},{"key":"BFleu2016202_CR21","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","volume":"119","author":"GL Uy","year":"2012","unstructured":"Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917\u20133924.","journal-title":"Blood"},{"key":"BFleu2016202_CR22","doi-asserted-by":"publisher","first-page":"e48929","DOI":"10.1371\/journal.pone.0048929","volume":"7","author":"AM McCaig","year":"2012","unstructured":"McCaig AM, Cosimo E, Leach MT, Michie AM . Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. PLoS One 2012; 7: e48929.","journal-title":"PLoS One"},{"key":"BFleu2016202_CR23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997\u20131007.","journal-title":"N Engl J Med"},{"key":"BFleu2016202_CR24","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390\u20133397.","journal-title":"Blood"},{"key":"BFleu2016202_CR25","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603\u20133612.","journal-title":"Blood"},{"key":"BFleu2016202_CR26","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1182\/blood-2008-06-165068","volume":"113","author":"M Niedermeier","year":"2009","unstructured":"Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113: 5549\u20135557.","journal-title":"Blood"},{"key":"BFleu2016202_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrclinonc.2014.42","volume":"11","author":"JA Burger","year":"2014","unstructured":"Burger JA, Okkenhaug K . Idelalisib\u2014targeting PI3K. Nat Rev Clin Oncol 2014; 11: 184\u2013186.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu2016202_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nri1780","volume":"6","author":"T Nagasawa","year":"2006","unstructured":"Nagasawa T . Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6: 107\u2013116.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2016202_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 2014; 4: 554\u2013563.","journal-title":"Cancer Discov"},{"key":"BFleu2016202_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014; 4: 546\u2013553.","journal-title":"Cancer Discov"},{"key":"BFleu2016202_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","volume":"21","author":"BW Miller","year":"2015","unstructured":"Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N et al. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res 2015; 21: 1525\u20131529.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016202_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1056\/NEJMe1400055","volume":"370","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Cantley LC . Idelalisib\u2014a PI3K\u03b4 inhibitor for B-cell cancers. N Engl J Med 2014; 370: 1061\u20131062.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2016202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016202","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:05:46Z","timestamp":1684418746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFleu2016202"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.202","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,27]]},"assertion":[{"value":"21 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}